\
Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancerNew Podcast

Turning the Tide on Cancer

Investing in Cardiff Oncology to Provide New Treatment Options for Cancers with the Greatest Medical Need

Stock Quote

NASDAQCRDF
$4.52
NASDAQCRDF
Open
$4.79
Change
-$0.25 (-5.15%)
Day's Range
$4.43 - $4.86
52-Week Range
$0.71 - $5.75
Volume
651.1K
Market Cap
$77.9M